Scarica l'app Stockscreener
3.16
4.53%
-0.15
Pre-mercato:
3.17
0.010
+0.32%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché RXRX Giù?
Forum
Previsione
Recursion Pharmaceuticals Inc Borsa (RXRX) Ultime notizie
Recursion Pharmaceuticals (RXRX) Stock Dropped, So What Is Behind The Move? - Sahm
RXRX Stock Soars Pre-Market On Q4 Beat, Recursion CEO Says Company Has ‘Reached An Inflection Point’ - Stocktwits
RXRX|Recursion Pharmaceuticals Inc|Price:3.160|Chg%:-0.150 - TradingKey
Recursion Pharmaceuticals | 144: Notice of proposed sale of securities pursuant to Rule 144 - Moomoo
Recursion Pharmaceuticals Stock Short Interest Rises to 35.35% - Moomoo
Jim Cramer: Utilities Stocks 'Oversold,' Fastly 'Back From Abyss'Cloudflare (NYSE:NET), Akamai Technol - Benzinga
Recursion Pharmaceuticals, Inc. (RXRX) Stock Price, News, Quote & History - Yahoo! Finance Canada
$Recursion Pharmaceuticals (RXRX.US)$ panic selling by retail investors... [Awkward] - Moomoo
Recursion (RXRX) Q2 2026 Earnings Call Transcript - AOL.com
Recursion Pharmaceuticals Stock (RXRX) Opinions on Pipeline Catalysts - Quiver Quantitative
Recursion Pharmaceuticals (RXRX) Institutional Ownership 2026 $RXRX - MarketBeat
Stock Traders Purchase High Volume of Put Options on Recursion Pharmaceuticals (NASDAQ:RXRX) - MarketBeat
The Biggest IPO of the Year Is Targeted in the Next 60 Days. Why One Unexpected Industry Could Rally Before Then (Hint: It's Not Tech) - 24/7 Wall St.
Recursion Pharmaceuticals, Inc. (RXRX) Stock Analysis: Potential Upside of Over 120% Sparks Investor Interest - DirectorsTalk Interviews
Recursion Pharmaceuticals faces slow growth and cash burn despite AI drug discovery partnerships. - Pluang
Recursion Pharmaceuticals: I'm Still Bearish Despite Recent Genentech News (NASDAQ:RXRX) - Seeking Alpha
Recursion Pharmaceuticals (RXRX) Is Up 7.3% After Mixed Q2 Results With Narrower Net Loss - Sahm
What Does The Future Hold For Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)? These Analysts Have Been Cutting Their Estimates - Moomoo
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Analysts Just Trimmed Their Revenue Forecasts By 19% - simplywall.st
Recursion Pharmaceuticals, Inc. 2026 Q2ResultsEarnings Call Presentation (NASDAQ:RXRX) 2026-08-09 - Seeking Alpha
Recursion Pharmaceuticals (NASDAQ:RXRX) Cut to "Strong Sell" at Wall Street Zen - MarketBeat
Recursion Pharmaceuticals (RXRX) Reported Q2 Revenue Pressure, Is The Valuation Gap Too Wide? - simplywall.st
Recursion Pharmaceuticals director Blake Borgeson sells $97,500 in stock By Investing.com - Investing.com South Africa
Recursion Pharmaceuticals Inc (RXRX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Recursion Pharmaceuticals | SCHEDULE 13G: Others - Moomoo
Recursion Pharmaceuticals Inc (RXRX) Stock Analysis & Forecast - TradingKey
Recursion Pharmaceuticals (RXRX) Director Blake Borgeson Sells 3 - GuruFocus
Blake Borgeson Sells 30,000 Shares of Recursion Pharmaceuticals (NASDAQ:RXRX) Stock - MarketBeat
Recursion Pharmaceuticals (RXRX) director sells 30,000 shares in 10b5-1 plan - Stock Titan
Recursion Pharmaceuticals Insiders Sell US$790k Of Stock, Possibly Signalling Caution - Moomoo
Bank of New York Mellon Corp Boosts Stake in Recursion Pharmaceuticals, Inc. $RXRX - MarketBeat
Recursion Pharmaceuticals (RXRX) Stock Looks Weak On Returns While Trading Above Fair Value - simplywall.st
Recursion Pharmaceuticals, Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
Recursion Pharmaceuticals (NASDAQ:RXRX) Releases Earnings Results, Misses Estimates By $0.01 EPS - MarketBeat
Recursion Pharmaceuticals Q2 Earnings Call Highlights - MarketBeat
Recursion Pharmaceuticals Releases Q2 2026 Financial Results - AlphaStreet
Earnings call transcript: Recursion misses Q2 2026 revenue forecast, shares fall premarket - Investing.com
Recursion Pharmaceuticals (NASDAQ:RXRX) Shares Gap Down Following Weak Earnings - MarketBeat
Recursion Pharmaceuticals Shares Fall After Q2 Miss - marketscreener.com
Recursion Pharmaceuticals, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Recursion Pharmaceuticals (RXRX) Stock Still Looks Expensive Following August 5 Results Update - Yahoo Finance
Earnings Flash (RXRX) Recursion Pharmaceuticals Inc Reports Q2 Revenue $7.7M - marketscreener.com
Recursion Pharmaceuticals: Q2 Earnings Snapshot - marketscreener.com
Recursion Pharmaceuticals 2026: Revenue $7.67M, EPS ($0.25) — 10-Q Summary - TradingView
Recursion Pharmaceuticals (NASDAQ: RXRX) gains Genentech milestone, highlights FAP drug progress - Stock Titan
Earnings To Watch: Recursion Pharmaceuticals Inc (RXRX) Q2 2026 -- GF Value Sees 43% Upside - GuruFocus
Recursion Pharmaceuticals Number of Employees 2026 | Employee Count & Headcount Data - Revelio Labs
Recursion Pharmaceuticals in focus as earnings test AI promise By Investing.com - Investing.com Nigeria
Recursion Pharmaceuticals in focus as earnings test AI promise - Investing.com
Renaissance Technologies LLC Makes New $7.37 Million Investment in Recursion Pharmaceuticals, Inc. $RXRX - MarketBeat
Recursion Pharmaceuticals (RXRX): Investor Outlook on a Biotech Pioneer with 127.99% Potential Upside - DirectorsTalk Interviews
Recursion Pharmaceuticals Inc expected to post a loss of 23 cents a shareEarnings Preview - TradingView
First Trust Advisors LP Has $8.02 Million Holdings in Recursion Pharmaceuticals, Inc. $RXRX - MarketBeat
Recursion Pharmaceuticals, Inc. Revenue Breakdown – NASDAQ:RXRX - TradingView
Recursion Pharmaceuticals Stock (RXRX) Opinions on AI Drug Discovery Pipeline and Recent Financial Results - Quiver Quantitative
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Receives Consensus Recommendation of "Hold" from Brokerages - MarketBeat
Recursion Pharmaceuticals (RXRX) Sees a More Significant Dip Than Broader Market: Some Facts to Know - Yahoo Finance
Recursion Pharmaceuticals (RXRX) Expected to Post Earnings on Tuesday - MarketBeat
Recursion Pharmaceuticals (RXRX) Exceeds Market Returns: Some Facts to Consider - Yahoo Finance Singapore
Recursion Pharmaceuticals, Inc. Class A Revenue Breakdown – BIVA:RXRX - TradingView
RXRX (RXRX) insider details 50,000-share planned sale and recent stock trades - Stock Titan
RXRX|Recursion Pharmaceuticals Inc|Price:3.030| - TradingKey
Recursion Pharmaceuticals Inc (RXRX) Cash Flow - TradingKey
AI Stocks: Why Tempus AI (NASDAQ:TEM), Recursion Pharmaceuticals (NASDAQ:RXRX) and Schrodinger (NASDAQ:SDGR) Are in Focus - Kalkine Media
TradingKey - TradingKey
0.52%
0.07%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):